Valmor 49 mg+51 mg (Tablet)
Unit Price: ৳ 85.00 (1 x 10: ৳ 850.00)
Strip Price: ৳ 850.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Square pharmaceuticals plc |
| Also available as |
Indications
- Reduces risk of cardiovascular death and hospitalization for heart failure
- Treats symptomatic heart failure in pediatric patients
- Administered in conjunction with other heart failure therapies
Pharmacology
- Contains neprilysin inhibitor, sacubitril, and angiotensin receptor blocker, valsartan
- Inhibits neprilysin and blocks angiotensin II type-1 receptor
- Effects attributed to increased levels of peptides degraded by neprilysin and simultaneous inhibition of angiotensin II effects
Dosage & Administration
- Recommended starting dose for adults: 49/51 mg twice daily
- Double the dose after 2 to 4 weeks to the target maintenance dose
- Recommended starting dose for pediatric patients: varies based on weight categories
Interaction
- Should not be used with ACE inhibitors or aliskiren in patients with diabetes
- Avoid use with ARB
- Potassium-sparing diuretics may increase serum potassium level
- NSAIDs may increase risk of renal impairment
- Increased risk of lithium toxicity with lithium
Contraindications
- Contraindicated in patients with hypersensitivity to any component
- In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy
- Do not administer within 36 hours of switching from or to an ACE inhibitor
- Contraindicated with concomitant use of aliskiren in patients with diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired renal function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year of age
- No relevant pharmacokinetic differences observed in elderly patients
- No dose adjustment required in patients with mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
- No dose adjustment required in patients with mild to moderate renal impairment
- Starting dose in patients with severe renal impairment: 24/26 mg twice daily
Precautions & Warnings
- May cause angioedema and must not be used in patients with a known history of angioedema
- May cause symptomatic hypotension
- Monitor serum creatinine and renal function
- Monitor serum potassium periodically and treat appropriately
- Dosage reduction or interruption may be required for hyperkalemia
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No starting dose adjustment needed for mild or moderate renal impairment
- Starting dose of 24/26 mg twice daily recommended for moderate hepatic impairment
- Not recommended for use in severe hepatic impairment
Overdose Effects
- Limited data available on overdosage
- Likely result of overdosage is hypotension
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis due to high protein binding
Storage Conditions
- Store in a dry place below 30°C
- Protect from moisture
- Keep out of the reach of children